Lille, France - Recently, the Transcatheter Mitral Valve Replacement System ("TMVR System") of MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as " MicroPort^® CardioFlow ") has successfully completed its first overseas clinical application under compassionate use at Lille University Center Hospital in France. The procedure, led by Prof. Thomas Modine's team at the hospital, resulted in a stable recovery for the patient, with good hemodynamic improvement, and the patient was discharged after recovery. The 30-day follow-up results showed complete disappearance of mitral regurgitation, no perivalvular leakage, and the valve was in good working order and stable position.

Moscow, Russia- On December 18, 2023, MicroPort^® CardioFlow completed the first implantation of its VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^®) in Russia, marking the completion of a highly complex Type 0 bicuspid aortic valve implantation with an extremely horizontally positioned heart via Transcatheter Aortic Valve Implantation (TAVI). Led by Professor Imaev Timur of the Russian National Medical Research Center for Cardiovascular Surgery, with guidance from Chinese experts, the team achieved precise deploy and successful release of the valve without the need for post-dilation. Post-operative echocardiography showed good valve shape and position, with no paravalvular leakage or conduction abnormalities, confirming the success of the procedure.

Shanghai, China-Recently, the second-generation balloon catheter-Alwide Plus Balloon Catheter (hereinafter referred to as "Alwide Plus") self-developed by MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) was approved for marketing by Saudi Food & Drug Authority.